Therapeutic applications of angiotensin II receptor antagonists

The renin-angiotensin system (RAS) represents today one of the most strateg ic targets of the therapy of cardiovascular diseases. During the last 30 ye ars a number of more or less successful approaches to inhibit the activity of the RAS have been attempted. In particular, the use of ACE-inhibitiors h as led to significant improvments in the outcom/treatment of hypertension, congestive heart failure, ischemic heart disease and nephropathies. On the other hand, Ace-inhibitors are not specifically targeted to RAS since they interfere with an enzyme with multiple different substrates. Furthermore, t he inhibition of ACE does not prevent the formation of angiotensin II throu gh alternative pathways, and thus the inhibition of RAS is often incomplete , especially under pathologic conditions stimulating RAS. For these reasons , the recent discovery of angiotensin ii receptors antagonists, which selec tively inhibit the action of angiotensin II at the level of the AT1 subtype receptor, is particularly attracting. This article reviews the background, the rationale and some of the clinical findings and potential applications with this new class of compounds.